Roche and Spark Therapeutics announced that Roche has extended the offering period of its previously announced tender offer to purchase all of the outstanding shares of common stock of Spark.
The offer was extended to provide additional time for the US Federal Trade Commission (FTC) and the UK Competition and Markets Authority (CMA) to complete their previously disclosed reviews of Roche’s pending acquisition of Spark. The parties remain committed to the transaction and are working cooperatively and expeditiously with the FTC and the CMA.
The companies had hoped to combine Roche, which makes the hemophilia treatment Hemlibra among many other drugs, with Spark, one of several biotech companies developing a gene therapy hemophilia cure among its projects, by last spring.
The US$4.3 billion sale, first announced in February, was the biggest payout for a gene therapy company since doctors at research hospitals including Children’s Hospital of Philadelphia and the University of Pennsylvania began gene therapy trials in the 1990s.
Full Content: Yahoo
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
T-Mobile’s Acquisition of Ka’ena Corporation Receives FCC Approval
Apr 26, 2024 by
CPI
UK Regulator Announces Two New Senior Executive Appointments
Apr 26, 2024 by
CPI
Paramount Global and Skydance Media Near Merger Deal, Eyeing CEO Change
Apr 26, 2024 by
CPI
BHP Unveils £31bn Mining Megamerger Proposal with Anglo American
Apr 25, 2024 by
nhoch@pymnts.com
ByteDance Prefers Shutdown Over Sale of TikTok Amid US Ban Threats
Apr 25, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI